Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.
Sponsor: Giselle Sholler
Terminated
Lack of enrollment and commercial availability of drug
Other terminated trials from Giselle Sholler
More terminations from Giselle Sholler
Listed as NCT01774253, this PHASE2 trial focuses on Pontine Glioma and remains terminated or withdrawn. Sponsored by Giselle Sholler, it has been updated 8 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
May 2022 — Oct 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — May 2022 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Giselle Sholler
- Phoenix Children's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .